Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Trial to Evaluate Palifermin (rHuKGF) in the Reduction of Acute Graft Versus Host Disease in Subjects With Hematologic Malignancies Undergoing Allogeneic Marrow/PBPC Transplantation

NCT00189488 is registered in ClinicalTrials.gov with Swedish Orphan Biovitrum as lead sponsor.

NCT NCT00189488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00189488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Trial to Evaluate Palifermin (rHuKGF) in the Reduction of Acute Graft Versus Host Disease in Subjects With Hematologic Malignancies Undergoing Allogeneic Marrow/PBPC Transplantation
Lead sponsor
Swedish Orphan Biovitrum
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2005
Completion date
August 31, 2013
Enrollment
155 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

graft versus host disease, hematologic malignancies